

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

**RECEIVED**  
 19 NOV 2004

PCT

NOTIFICATION OF TRANSMITTAL OF  
 THE INTERNATIONAL PRELIMINARY  
 EXAMINATION REPORT  
 (PCT Rule 71.1)

To:  Franks, Barry AMERSHAM PLC Amersham Place Little Chalfont Buckinghamshire HP7 9NA GRANDE BRETAGNE	DUE DATE:	—			
	FORMALITIES:	FISL ✓			
	PAT. OFF:	MRB	C		
	ON DB:	—			
	CASE NO:	PA0254-PCT			

Date of mailing (day/month/year)	18.11.2004
-------------------------------------	------------

Applicant's or agent's file reference  
PA0254-PCT

## IMPORTANT NOTIFICATION

International application No. PCT/GB 03/03196	International filing date (day/month/year) 28.07.2003	Priority date (day/month/year) 30.07.2002
--	--	--

Applicant  
AMERSHAM BIOSCIENCES UK LIMITED

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

### 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international preliminary examining authority:



European Patent Office - P.B. 5818 Patentlaan 2  
 NL-2280 HV Rijswijk - Pays Bas  
 Tel. +31 70 340 - 2040 Tx: 31 651 epo nl  
 Fax: +31 70 340 - 3016

Authorized Officer

Cherqui, E

Tel. +31 70 340-2643



## PATENT COOPERATION TREATY



## PCT

REC'D 17 NOV 2004

WIPO

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT  
(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PA0254-PCT	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA/416)	
International application No. PCT/GB 03/03196	International filing date (day/month/year) 28.07.2003	Priority date (day/month/year) 30.07.2002
International Patent Classification (IPC) or both national classification and IPC C09B23/08		
Applicant AMERSHAM BIOSCIENCES UK LIMITED		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 4 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the opinion</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>		
Date of submission of the demand  04.02.2004	Date of completion of this report  18.11.2004	
Name and mailing address of the international preliminary examining authority:  European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016	Authorized Officer  Ginoux, C  Telephone No. +31 70 340-2839 	

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/GB 03/03196

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, Pages**

1-26 as originally filed

**Claims, Numbers**

1-19 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).
3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:
- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
4. The amendments have resulted in the cancellation of:
- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:
5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).
- (Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*
6. Additional observations, if necessary:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/GB 03/03196

---

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;  
citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes: Claims	1-19
	No: Claims	
Inventive step (IS)	Yes: Claims	1-19
	No: Claims	
Industrial applicability (IA)	Yes: Claims	1-19
	No: Claims	

**2. Citations and explanations**

**see separate sheet**

**Re Item V**

**Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

Reference is made to the following document:

D1: SCHULER BENJAMIN ET AL: "Specific labeling of polypeptides at amino-terminal cysteine residues using Cy5-benzyl thioester" BIOCONJUGATE CHEMISTRY., vol. 13, no. 5, 18 July 2002 (2002-07-18), pages 1039-43, XP002259205 AMERICAN CHEMICAL SOCIETY, WASHINGTON., US ISSN: 1043-1802

Although some unclarity can be seen in the formulation of present claim 1, especially the reference to the desirable characteristic or property of a group "suitable for covalent reaction with a thioester", the International Search Report has not revealed any document disclosing subject-matter detrimental for the assessment of Novelty of the present application. In particular no document discloses cyanine dyes containing a target bonding group such as a carboxylic acid thioester group or a 1,2-aminothiol group and an affinity tag. The subject-matter of the present application is therefore new (Article 33(2) PCT).

The document D1 is regarded as being the closest prior art to the subject-matter of claim 1 and discloses the labelling of polypeptides at amino-terminal cysteine residues using Cy5-benzyl thioester.

The subject-matter of the present application differs from D1 in that the claimed compounds additionally contain an affinity tag which is advantageous for the separation and purification of the dye-labelled target.

The problem to be solved can be seen in the provision of cyanine dyes reporters allowing site-specific labelling of proteins or peptides and enabling easy separation and purification of the labelled proteins or peptides.

Since there is no indication in the prior art that could have lead a skilled person to modify compounds such as those disclosed in D1 by incorporation of an affinity tag, the subject-matter of the present application is considered as involving an inventive step (Article 33(3) PCT).